Meeting
2023 ASCO Annual Meeting
Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.
Authors
Dan-yun Ruan
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China
Dan-yun Ruan , Myung Ah Lee , Yanhong Deng , Keun-Wook Lee , Michael Millward , Jaspreet Singh Grewal , Shirish M. Gadgeel , Rachel E. Sanborn , Xinfang Hou , Shaozhong Wei , Seok Jae Huh , Fu-Rong Liu , Xiaoxi Xie , Ziyong Xiang , Zhe Shi , Yaolin Wang , Ling Zhang , Gary Edward Richardson , Rui-Hua Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT04585035
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3563)
DOI
10.1200/JCO.2023.41.16_suppl.3563
Abstract #
3563
Poster Bd #
263
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.
First Author: Tanios S. Bekaii-Saab
Poster
2016 Gastrointestinal Cancers Symposium
Impact of first-line bevacizumab therapy on the efficacy of subsequent anti-epidermal growth factor antibodies (anti-EGFR) in metastatic colorectal cancer (mCRC).
First Author: Matthew E. Burge
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study.
First Author: Antoine Hollebecque
Poster
2023 ASCO Annual Meeting
Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor, in patients with locally advanced or metastatic breast cancer: Updated results from an on-going phase II study.
First Author: Tamta Makharadze